Zymeworks (ZYME) EBITDA (2021 - 2026)
Zymeworks (ZYME) posted EBITDA of -$47.1 million for Q1 2026, down 6.72% sequentially from -$44.2 million in Q4 2025, and down 83.96% YoY from -$293.8 million in Q1 2025.
Zymeworks (ZYME) EBITDA (2021 - 2026) Analysis & Trends
Zymeworks has reported EBITDA for 6 years, with the latest figure at -$47.1 million in Q1 2026.
- Quarterly EBITDA fell 83.96% year-over-year to -$47.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.1 million (up 8.7% YoY) and the FY2025 annual result came in at -$92.5 million, up 32.5% from the prior year.
- EBITDA fell to -$47.1 million in Q1 2026 per ZYME's latest filing, from -$44.2 million in the prior quarter.
- Over five years, EBITDA peaked at $319.4 million in Q4 2022 and troughed at -$72.7 million in Q1 2022.
- A 5-year average of -$16.7 million and a median of -$34.2 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2023: EBITDA soared 881.89% in 2022, then tumbled 107.33% in 2023.
- Over 5 years, EBITDA stood at $319.4 million in 2022, then plunged by 107.33% to -$23.4 million in 2023, then advanced by 5.14% to -$22.2 million in 2024, then slumped by 98.73% to -$44.2 million in 2025, then slipped by 6.72% to -$47.1 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$47.1 million, -$44.2 million, and -$22.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Zymeworks | 1.79 Bn | 1.52 Bn | - | -42.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -42.18 Mn |
| Mar 31, 2026 | -47.12 Mn |
| Dec 31, 2025 | -44.15 Mn |
| Sep 30, 2025 | -22.11 Mn |
| Jun 30, 2025 | -674,000.00 |
| Mar 31, 2025 | -25.61 Mn |
| Dec 31, 2024 | -22.22 Mn |
| Sep 30, 2024 | -34.21 Mn |
| Jun 30, 2024 | -42.89 Mn |
| Mar 31, 2024 | -37.80 Mn |
| Dec 31, 2023 | -23.42 Mn |
| Sep 30, 2023 | -33.24 Mn |
| Jun 30, 2023 | -54.11 Mn |
| Mar 31, 2023 | -27.28 Mn |
| Dec 31, 2022 | 319.40 Mn |
| Sep 30, 2022 | -50.36 Mn |
| Jun 30, 2022 | -65.82 Mn |
| Mar 31, 2022 | -72.69 Mn |
| Dec 31, 2021 | -40.85 Mn |
| Sep 30, 2021 | -60.96 Mn |